Gelonghui June 27th 丨Ricoh Bio-B (02179.HK) announced that the Group has recently announced its novel coronavirus mRNA vaccine R520A (”R520A”) Approved for clinical trials by the Philippine National Food and Drug Administration (”Clinical trial approval“).

R520a is an mRNA vaccine developed by Wuhan Ricoh Biotechnology Co., Ltd., a subsidiary of the company, for the novel coronavirus Omicron variant. Using self-developed freeze-drying technology, R520A can effectively maintain the physico-chemical properties and biological activity of mRNA-LNP and achieve long-term storage at 2-8°C.

Preclinical studies showed that the product raised the titer level of the neutralizing antibody against the Omicron variant to a high level of 4,758, and could induce a neutralization response against the delta variant, showing good immunogenic characteristics.